Sage Therapeutics Company Profile (NASDAQ:SAGE)

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $69.20 (54.26% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016William BlairReiterated RatingOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Chardan CapitalReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016BMO Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Leerink SwannReiterated RatingBuy$66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015SunTrust Banks Inc.Initiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.03)
Q3 20164($1.22)($0.98)($1.09)
Q4 20164($1.29)($1.00)($1.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sage Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline
07/28/16 04:24 PMHow To Get A 1-On-1 With An Expert On SAGE-547 -
07/25/16 08:14 AMImportance Of Phase 2 Trials -
07/22/16 06:02 PMForm 8-K Sage Therapeutics, Inc. For: Jul 15 - StreetInsider.com
07/22/16 06:02 PMSage Therapeutics Incorporated (NASDAQ:SAGE) Sellers Increased By 20.32% Their Shorts - Consumer Eagle
07/22/16 06:02 PMWhat's Next for SAGE Therapeutics Inc After Today's Huge Increase? - Consumer Eagle
07/22/16 02:18 PMEdited Transcript of SAGE earnings conference call or presentation 5-May-16 8:30pm GMT -
07/21/16 03:11 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem -
07/21/16 09:04 AMEarnings Focus and Crowd Sourced Sentiment Review for Sage Therapeutics, Inc. (NASDAQ:SAGE) - TGP
07/20/16 07:06 PMSage Therapeutics, Inc. (NASDAQ:SAGE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 07:06 PMSolid Performer in Focus: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/19/16 06:00 AMSage Appoints Geno Germano to Company's Board of Directors - [Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage’s Board of Directors.
07/18/16 11:50 AMTrading Performance and Target Watch for Sage Therapeutics, Inc. (NASDAQ:SAGE) - Press Telegraph
07/18/16 11:50 AMStock in Positive Territory for the Quarter: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/18/16 11:50 AMShares of Sage Therapeutics (SAGE) Rally 24.29% - Trade Calls
07/13/16 06:40 PMDid SAGE Therapeutics Inc (NASDAQ:SAGE) Just Cure Depression?
07/13/16 03:58 PMSAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/13/16 09:07 AMRatings Analysis of: Sage Therapeutics, Inc. (NASDAQ:SAGE) - News Oracle
07/13/16 09:07 AMJP Morgan Reiterates Overweight on SAGE Therapeutics Inc (SAGE) Following Positive Top-Line Phase 2 Data - Smarter Analyst
07/13/16 09:07 AMBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc - Schaeffers Research (blog)
07/13/16 09:07 AMSage Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/13/16 08:26 AMCoverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics -
07/12/16 06:29 PMHere's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today
07/12/16 05:14 PMAfter-hours buzz: JUNO, TEVA, SAGE & more -
07/12/16 04:19 PMSage Therapeutics shares soar on positive postpartum depression drug results -
07/12/16 03:31 PMSage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results -
07/12/16 10:39 AMSage's Phase 2 Clinical Trial Of SAGE-547 Achieves Primary Endpoint In Severe Postpartum Depression
07/12/16 10:39 AMSage Surges After Postpartum Drug Meets Goals in Trial
07/12/16 10:39 AMSage's drug for postpartum depression succeeds in mid-stage study
07/12/16 10:39 AMSage Therapeutics (SAGE) Boosted by Promising Postpartum Depression Drug Data
07/12/16 10:39 AMBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc
07/12/16 10:39 AMStocks to Watch: Starbucks, Sage Therapeutics, Seagate Technology
07/12/16 10:39 AMSage Therapeutics' postpartum depression drug succeeds in study
07/12/16 10:27 AMSage Therapeutics: That's Some Data! -
07/12/16 09:39 AMSage Therapeutics Inc: SAGE Stock Jumps 40% on Phase-2 PPD Results - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Sage Therapeutics Inc (SAGE) may find itself as the one and only serious player in this niche sliver of the depression market. The post Sage Therapeutics Inc: SAGE Stock Jumps 40% on Phase-2 PPD Results appeared first on InvestorPlace.
07/09/16 05:36 PMWere Analysts Bullish SAGE Therapeutics Inc (NASDAQ:SAGE) This Week? - Engelwood Daily
07/08/16 06:14 PMSage Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 06:18 PMEssential Tremor Pipeline Review 2016 Featuring Merz GmbH & Co., Neurocrine Biosciences & Sage Therapeutics - Research and Markets
07/07/16 09:02 AMStock Tracking Down This Month; Investor Alert on Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily
07/07/16 09:02 AMInsiders are Gradually Selling Sage Therapeutics, Inc. (NASDAQ:SAGE) - Telanagana Press
07/07/16 09:02 AMBMO Capital Initiates Coverage on SAGE Therapeutics Inc to Outperform - TheFounders Daily
07/05/16 10:42 AMBroker Outlook For The Week Ahead Sage Therapeutics, Inc. (SAGE) - Fiscal Standard
07/02/16 05:49 PMHow Analysts Feel About SAGE Therapeutics Inc (NASDAQ:SAGE)? - Press Telegraph
07/01/16 02:20 PMBiotech catalysts -
06/30/16 06:29 PMH.C. Wainwright Initiates Coverage on SAGE Therapeutics Inc to Buy - Trade Calls
06/30/16 09:03 AMIs Sage Therapeutics (NASDAQ:SAGE) Worth Your Time? BMO Capital Thinks So - Press Telegraph
06/28/16 06:08 PMOption Market: Sage Therapeutics Inc. Risk Hits An Extreme High - CML News
06/28/16 11:03 AMSAGE Therapeutics : Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics
06/27/16 10:25 AMHot Stock List: Sage Therapeutics, Inc. (NASDAQ:SAGE), Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL ... - KC Register
06/27/16 10:25 AMNext Weeks Broker Price Targets For Sage Therapeutics, Inc. (SAGE) - Fiscal Standard
06/25/16 09:59 AMSage Therapeutics (NASDAQ:SAGE) stock price target bumped up to $56 as recorded today by H.C. Wainwright

Social

About Sage Therapeutics

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $44.86
  • 50 Day Moving Average: $35.43
  • 200 Day Moving Average: $34.48
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.44B
  • Beta: 2.35
  • Current Year EPS Consensus Estimate: $-4.23 EPS
  • Next Year EPS Consensus Estimate: $-4.64 EPS
Additional Links:
Sage Therapeutics (NASDAQ:SAGE) Chart for Saturday, July, 30, 2016